Jump to content

Ginkgo Bioworks

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Ceyockey (talk | contribs) at 03:06, 22 December 2022 (added citation). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ginkgo Bioworks Holdings, Inc.
Company typePublic company
IndustryBiotechnology
Founded2009; 16 years ago (2009) in Boston, Massachusetts, U.S.
FoundersTom Knight, Jason Kelly, Reshma Shetty, Barry Canton, Austin Che
Headquarters,
U.S.
Key people
RevenueIncrease US$313.84 million (2021)[1]
Decrease US$−1.83 billion (2021)[1]
Decrease US$−1.83 billion (2021)[1]
Total assetsIncrease US$2.07 billion (2021)[1]
Total equityIncrease US$1.57 billion (2021)[1]
Number of employees
641 (Dec 2021)[1]
Websiteginkgobioworks.com

Ginkgo Bioworks is an American biotech company founded in 2009 by scientists from MIT and headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications.[2][3][4][5] Ginkgo Bioworks is an analytics company that designs microorganisms for customers in a range of industries. It is the self-proclaimed "Organism Company" and was one of the world's largest privately held biotech companies,[6] valued at $4.2 billion in 2019.[7] It raised $290 million in September and $350 million in October of that year.[6]

History

On 16 December 2020, it was reported that Ginkgo Bioworks would acquire the primary assets of Novogy's Microbial Engineering Platform.[8][9][self-published source]

On 11 May 2021, Gingko Bioworks announced plans of going public through a merger with SPAC Soaring Eagle at a $17.5 billion valuation.[10]

On 14 May 2021, Ginkgo announced its new ticker for the NYSE will be "DNA". The ticker was previously used by Genentech, who stopped using the ticker after they were acquired by Roche.[11][self-published source] Trading began on September 17, 2021.[12][13][self-published source] The investment management firm Baillie Gifford became the largest shareholder (15%) with the purchase of 167.75 million shares on 31 March 2022.[14]

On 14 March 2022, it was reported that Ginkgo Bioworks signed a Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform.[15][self-published source]

On 6 June 2022, it was reported that Ginkgo Bioworks has acquired assets from Bitome, an Integrated Metabolite Monitoring Platform.[16][self-published source]

On 25 July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal.[17]

On 27 July 2022, it was reported that Ginkgo Bioworks would acquire Bayer's Biologics Research & Development site, located in West Sacramento. Ginko will enter into a new multi-year platform collaboration with Bayer. The deal includes the integration of the R&D platform assets from Joyn Bio, a joint-venture between Leaps by Bayer investments and Ginkgo Bioworks.[18]

On 4 October 2022, it was reported that Ginkgo Bioworks would acquire France-based adaptive laboratory evolution instruments developer Altar and California-based Circularis to strengthen capabilities in cell and gene therapy.[19][20][21]

In October 2022, Bloomberg News reported that Ginkgo Bioworks partnered with Intelligence Advanced Research Projects Activity to create a software tool to help detect when biological organisms have been genetically engineered. The tool known as ENDAR (short for Engineered Nucleotide Detection and Ranking) could be used to provide an early warning of bioweapons and other man-made biological threats.[22]

See also

References

  1. ^ a b c d e f "Ginkgo Bioworks Holdings, Inc. 2021 Form 10-K Report". U.S. Securities and Exchange Commission. 29 March 2022.
  2. ^ Molteni, Megan (14 September 2017). "With Designer Bacteria, Crops One Day Could Fertilize Themselves". Wired. Archived from the original on 5 December 2017. Retrieved 4 December 2017.
  3. ^ Herper, Mathew (8 June 2016). "Boston Startup Raises $100 Million To Use Synthetic Biology To Design Microbes For Industry". Forbes. Archived from the original on 9 Jun 2016. Retrieved 4 December 2017.
  4. ^ Adams, Susan (14 September 2017). "Bayer And Ginkgo Bioworks, A Startup, Aim To Make Crops Produce Their Own Nitrogen Fertilizer". Forbes. Archived from the original on 5 December 2017. Retrieved 4 December 2017.
  5. ^ Weisman, Robert (29 September 2016). "Ginkgo Bioworks opens production site for custom cells". Boston Globe. Retrieved 4 December 2017.
  6. ^ a b Spalding, Rebecca (9 October 2019). "Ginkgo Bioworks raises $350 million fund for biotech spinouts". Reuters. Archived from the original on 7 November 2019. Retrieved 7 November 2019.
  7. ^ Weber, Joel (6 November 2019). "Ginkgo Bioworks CEO Wants Biology to Manufacture Physical Goods". Bloomberg News. Retrieved 7 November 2019.
  8. ^ Price, Thomas (9 January 2021). "Startup Novogy Acquired by Ginkgo Bioworks". Archived from the original on 9 January 2021. Retrieved 21 December 2022.
  9. ^ "Ginkgo Bioworks Acquires Biotechnology Startup Novogy's Microbial Engineering Platform" (Press release). Ginkgo Bioworks. 16 December 2020. Archived from the original on 4 October 2022. Retrieved 4 October 2022 – via CISION PR Newswire.
  10. ^ Nishant, Niket (11 May 2021). "Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $17.5 billion deal". Reuters. Archived from the original on 11 May 2021. Retrieved 12 May 2021.
  11. ^ "Taking Ginkgo Public on NYSE:DNA". Ginkgo Bioworks. 14 May 2021. Archived from the original on 15 May 2021. Retrieved 15 May 2021.
  12. ^ de León, Riley (17 September 2021). "Ginkgo Bioworks begins trading on the NYSE after completing SPAC merger". CNBC. Archived from the original on 17 September 2021. Retrieved 17 September 2021.
  13. ^ "Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds" (Press release). Ginkgo Bioworks. 14 September 2021. Archived from the original on 14 September 2021.
  14. ^ Pan, Eddie (7 April 2022). "Baillie Gifford Just Bought Ginkgo Bioworks (DNA) Stock. Here's Why". InvestorPlace. Archived from the original on 12 October 2022. Retrieved 21 December 2022.
  15. ^ "Ginkgo Bioworks Signs Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform" (Press release). Ginkgo Bioworks. Archived from the original on 4 October 2022. Retrieved 4 October 2022.
  16. ^ "Ginkgo Bioworks Acquires Bitome, an Integrated Metabolite Monitoring Platform" (Press release). Ginkgo Bioworks. 6 June 2022. Retrieved 4 October 2022.
  17. ^ Saul, Derek (25 July 2022). "Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million". Forbes. Archived from the original on 26 July 2022.
  18. ^ "Ginkgo and Bayer Sign Definitive Agreement to Build Agricultural Biologicals R&D Platform Capabilities". finance.yahoo.com. Retrieved 2022-10-05.
  19. ^ "Ginkgo Bioworks Acquires Adaptive Laboratory Evolution Company Altar". TipRanks Financial. Retrieved 2022-10-04.
  20. ^ PhD, Julianna LeMieux (2022-10-05). "Two Is Better Than One: Ginkgo Bioworks Acquires Altar and Circularis". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-05.
  21. ^ "Ginkgo Bioworks Acquires Circularis to Strengthen Capabilities in Cell and Gene Therapy". TipRanks Financial. Retrieved 2022-10-04.
  22. ^ Griffin, Riley (2022-10-17). "Ginkgo Is Trying to Detect Future Man-Made Biological Threats". Bloomberg News. Archived from the original on 2022-10-18.
  • Official website
  • Business data for Ginkgo Bioworks Holdings, Inc.: